Acumen Q3 net loss $10.7M; INTERCEPT-AD Phase 1 on track, FDA Fast Track granted

Acumen Pharmaceuticals, Inc.

2022-Q3 EPS reported -$0.74

Cash, equivalents & marketable securities $200.2M at Sep 30, 2022, sufficient through 2025.
R&D expenses $8.3M (Q3 2022) vs $1.8M (Q3 2021) due to clinical trial ramp.
INTERCEPT-AD enrollment expected to complete Q1 2023; topline data anticipated H2 2023.
FDA granted Fast Track designation for ACU193 in early Alzheimer's in October 2022.
Appointed Derek Meisner as Chief Legal Officer in September 2022.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Acumen Pharmaceuticals, Inc. reported the quarter ended September 30, 2022 results: net income $10.7 million.

Period: the quarter ended September 30, 2022
Net income: $10.7 million
Result: reported results

Exact text from the filing

Net loss was $10.7 million for the three-month period ended September 30, 2022

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

Acumen Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-284564

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.